| |
|
|
|
|
|
Somersworth, New Hampshire. J-PAC LLC, a medical device contract manufacturer and packager, has re-launched its website, www.j-pac.com, in a new look, highlighting the full range of the company’s services and its dedication to quality.
|
Company:
Date:
August 12, 2009
|
|
|
|
|
|
|
|
|
|
The mesh implant in the Advantage Mid-Urethral Sling System is intended for use as a mid-urethral sling for the treatment of stress urinary incontinence. The Advantage System includes an innovative mid-urethral sling that offers several advancements in delivery and tensioning, all of which are designed to meet the demands of the physician.
|
Company:
Date:
March 23, 2009
|
|
|
|
|
|
|
|
|
|
The Align® TO Trans-Obturator Urethral Support System (Align® TO Urethral Support System) is a suburethral sling device intended for the treatment of female stress urinary incontinence. The system comprises stainless steel trans-obturator introducers and a polypropylene mesh sling implant encased in a protective sheath with green guide tubes at each end of the sheath. Connectors are attached to the distal ends of the guide tubes, and are designed to attach to the tip portion of the introducer needles. The device is terminally sterilized by ethylene oxide.
|
Company:
Date:
March 23, 2009
|
|
|
|
|
|
|
|
|
|
The Align® Retropubic/Suprapubic/Retropubic-Suprapubic (R/S/RS) Urethral Support System (Align® Urethral Support System) is a suburethral sling device intended for the treatment of female stress urinary incontinence. The system comprises stainless steel introducers and a polypropylene mesh sling implant encased in a protective sheath with green guide tubes at each end of the sheath. Connectors are attached to the distal ends of the guide tubes, and are designed to attach to the tip portion of the introducer needles. The device is terminally sterilized by ethylene oxide.
|
Company:
Date:
March 23, 2009
|
|
|
|
|
|
|
|
|
|
The BioArc® System treats female stress urinary incontinence (SUI) with a minimally invasive procedure by placing a strip of biologic mesh in the body to provide support to the urethra. The BioArc is an innovative hybrid system combining both synthetic and biologic materials and is the only hybrid sling available on the market today.
Tensioning and loosening sutures are designed to maintain mesh integrity during placement and allow for intra-operative tensioning refinement without distorting the biologic graft material.
|
Company:
Date:
March 23, 2009
|
|
|
|
|
|
|
|
|
|
BioArc TO® uses proprietary centered helical needles designed to move away from the obtuarator canal, avoid the patient's retropubic space and minimize blind needle passage.
The Mesh
Knitted, polypropylene Type I mesh from AMS has been in over 400,000 patients and features large pores and open edges for fibrous tissue integration.
|
Company:
Date:
March 23, 2009
|
|
|
|
|
|
|
|
|
|
The Capio CL Transvaginal Suture Capturing Device is designed to facilitate transvaginal suture fixation to Cooper's Ligament.
|
Company:
Date:
March 23, 2009
|
|
|
|
|
|
|
|
|
|
Coaptite Injectable Implant, a next generation bulking agent, is designed to offer improved procedural ease of use, fewer reinjections, and less material volume versus other approved bulking agents while maintaining the durability characteristics of a synthetic product.
|
Company:
Date:
March 27, 2009
|
|
|
|
|
|
|
|
|
|
Contigen® Bard® Collagen Implant, the world's leading bulking therapy, is the least invasive implant option for the treatment of Stress Urinary Incontinence (SUI). Natural collagen protein adds bulk to surrounding urethral tissue to aid coaptation in a defective internal sphincter. Compatible with the body's own structure, Contigen® Bard® Collagen Implant forms a soft network of fibers, inducing new tissue growth at the injection site. Contigen® Bard® Collagen Implant is used successfully as stand-alone therapy or concomitant therapy supporting surgical sling or pelvic reconstructive repairs.
|
Company:
Date:
March 27, 2009
|
|
|
|
|
|
|
|
|
|
Delivers the durability of natural tissue with all the corresponding benefits of ingrowth and natural adaptation to surrounding tissues. Meets or exceeds all applicable state and federal tissue guidelines, FasLata® Allograft Tissue also reduces OR time and patient discomfort since no tissue is recovered from the patient.
|
Company:
Date:
March 23, 2009
|
|
|
|
|
|